Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Ezia BelloSilvia BrichIlaria CraparottaLaura MannarinoSara BallabioRaffaella GattaSergio MarchiniLaura CarrassaCristina MatteoRoberta SanfilippoAlessandro GronchiPaolo Giovanni CasaliSilvana PilottiMaurizio D'IncalciRoberta Frapolli

Published in: British journal of cancer (2019)

This is the first in vivo model of myxoid liposarcoma with acquired resistance to trabectedin. Although further studies are necessary to characterise the resistance mechanisms, this is a useful tool for studying new therapeutic strategies to overcome trabectedin resistance in patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
patient reported outcomes